Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock Exchange

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014. Oramed CEO Nadav Kidron will present the findings at an investor conference taking place at the Tel Aviv Stock Exchange in Tel Aviv, Israel.

The Phase 2a trial was conducted in the U.S. under the auspices of the FDA and was designed to show the drug's overall safety profile. Thirty patients with type 2 diabetes took part in the double-blind, randomized trial in an in-patient setting for one week of treatment.

Endo and BioDelivery Sciences Announce Positive Top-Line Results from the Phase III Clinical Trial of BEMA Buprenorphine in Opioid Naive Patients with Chronic Pain

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (ENDP), and BioDelivery Sciences International, Inc. (BDSI) announced today positive top-line results from its pivotal Phase 3 efficacy study of BEMA buprenorphine in opioid- "naive" subjects. BEMA buprenorphine is being developed for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy for an extended period of time in both patients who are opioid naive and opioid experienced. 

CEL-SCI Receives Government Approval in Serbia to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

World’s largest Phase III trial for head and neck cancer being conducted as cancer immunotherapy is named Breakthrough of the Year by Science Magazine

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received approval from the Medicines and Medical Device Agency of Serbia to begin enrollment of subjects in its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Serbia is the 11^th country from which approval to participate in the world’s largest Phase III trial for the treatment of head and neck cancer has been obtained. The clinical sites in Serbia are expected to become active in the next few weeks. Approximately 72 of the worldwide total of 880 patients for the study are expected to be enrolled in Serbia.

ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib

Data Monitoring Committee approves continuation of Phase 3 METIV-HCC liver cancer trial following safety and pharmacokinetic analyses

Asian partner Kyowa Hakko Kirin provides top-line data on ATTENTION trial in non-squamous non-small cell lung cancer

ArQule, Inc. (ARQL) today provided clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer) conducted by the Company and its partner, Daiichi Sankyo Co., Ltd., and on the completed amended Phase 3 ATTENTION trial in non-squamous non-small cell lung cancer (NSCLC) conducted in Asian territories by its partner, Kyowa Hakko Kirin Co., Ltd.